{"id":412771,"date":"2021-01-12T07:03:08","date_gmt":"2021-01-12T12:03:08","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=412771"},"modified":"2021-01-12T07:03:08","modified_gmt":"2021-01-12T12:03:08","slug":"point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/","title":{"rendered":"POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">TORONTO, Jan.  12, 2021  (GLOBE NEWSWIRE) &#8212; POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium \u2013 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer. CanProbe, a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC), developed Lu-DOTATATE as it is being used in 167 neuroendocrine tumor (NET) patients in a 180-patient trial with enrollment completed.<\/p>\n<p align=\"justify\">\u201cCanProbe\u2019s NET clinical program has helped many patients in Ontario who previously had no other options for treatment,\u201d says Dr. Joe McCann, Chief Executive Officer of POINT Biopharma. \u201cWe are excited to extend access to this treatment by leveraging CanProbe\u2019s intellectual property to seek regulatory approvals, with the goal of helping patients in need around the world.\u201d POINT is currently building a state-of-the-art manufacturing facility in Indianapolis, Indiana, to ensure sufficient production capacity is available for Lu-DOTATATE as well as the other drugs in its pipeline.<\/p>\n<p align=\"justify\">\u201cWe are looking forward to working with POINT Biopharma on the commercialization of Lu-DOTATATE,\u201d says Dr. Luke Brzozowski, President of CanProbe. \u201cWe believe POINT is the ideal partner to make this treatment accessible to patients in Ontario and across the globe.\u201d CanProbe is also developing the related diagnostic agent, Gallium \u2013 68 Octreotate (Ga-DOTATATE), with cyclotron-produced Ga-68 using solid target technology.<\/p>\n<p align=\"justify\">\n        <strong>About CanProbe <\/strong>\n      <\/p>\n<p align=\"justify\">CanProbe (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=c-booom5cg34ZH4XxjZx5q9AIqEggs48Pe9Moz8yHvidS3db43sNxzaT8CSovsj2Ht8p2ewXhrgPrIO1i04ytw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">canprobe.ca<\/a>) is a joint venture between the University Health Network (UHN, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VNmDT2Q3Pnqg3v0Tf0ZJGrTzhAONyhgUAhorkkV9aQKgCUHuWSCur68GC2LjpAXR\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">uhn.ca<\/a>) and the Centre for Probe Development and Commercialization (CPDC, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JMGAcS_XJCEooLY6AxOHDunDCrmNA9TwSmR4W8YUtKuW0d_CfpeFnNMbS-k7qaWj3AF4Ne7t3-hNLHrbF0JFzrZuXTSSz5CCBlGzTHJhqVw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">imagingprobes.ca<\/a>) to create a Canadian Centre of Excellence for the development, translation, utilization and commercialization of radiopharmaceuticals. CanProbe provides access to specialized expertise that supports the development of new radiopharmaceuticals, with proven experience translating products to the clinical setting, and world-class, GMP, manufacturing capabilities that operate in accordance with FDA, Health Canada and European regulations.<\/p>\n<p align=\"justify\">\n        <strong>About POINT Biopharma<\/strong>\n      <\/p>\n<p align=\"justify\">POINT Biopharma is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, strategic partnerships in radio-isotope supply, manufacturing technology and novel direct to patient targeting to revolutionize theragnostic drug development and radioligand commercialization.<\/p>\n<p align=\"center\">\n        \n      <\/p>\n<p align=\"left\">\n        <strong>Media Inquiries: <\/strong>\n      <\/p>\n<p align=\"left\">Ari Shomair<\/p>\n<p align=\"left\">VP, Corporate Affairs<br \/>media@pointbiopharma.com <br \/>(647) 812-2417<br \/>https:\/\/www.pointbiopharma.com<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc3OCMzOTEzMjgwIzIxOTQ1Njg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/02355715-3a9b-4fb6-a0e2-ad12c425089a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) &#8212; POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium \u2013 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer. CanProbe, a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC), developed Lu-DOTATATE as it is being used in 167 neuroendocrine tumor (NET) patients in a 180-patient trial with enrollment completed. \u201cCanProbe\u2019s NET clinical program has helped many patients in Ontario who previously had no other options for treatment,\u201d says Dr. Joe McCann, Chief Executive Officer of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-412771","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) &#8212; POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium \u2013 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer. CanProbe, a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC), developed Lu-DOTATATE as it is being used in 167 neuroendocrine tumor (NET) patients in a 180-patient trial with enrollment completed. \u201cCanProbe\u2019s NET clinical program has helped many patients in Ontario who previously had no other options for treatment,\u201d says Dr. Joe McCann, Chief Executive Officer of &hellip; Continue reading &quot;POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-12T12:03:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc3OCMzOTEzMjgwIzIxOTQ1Njg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment\",\"datePublished\":\"2021-01-12T12:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\\\/\"},\"wordCount\":407,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzc3OCMzOTEzMjgwIzIxOTQ1Njg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\\\/\",\"name\":\"POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzc3OCMzOTEzMjgwIzIxOTQ1Njg=\",\"datePublished\":\"2021-01-12T12:03:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzc3OCMzOTEzMjgwIzIxOTQ1Njg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzc3OCMzOTEzMjgwIzIxOTQ1Njg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/","og_locale":"en_US","og_type":"article","og_title":"POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment - Market Newsdesk","og_description":"TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) &#8212; POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium \u2013 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer. CanProbe, a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC), developed Lu-DOTATATE as it is being used in 167 neuroendocrine tumor (NET) patients in a 180-patient trial with enrollment completed. \u201cCanProbe\u2019s NET clinical program has helped many patients in Ontario who previously had no other options for treatment,\u201d says Dr. Joe McCann, Chief Executive Officer of &hellip; Continue reading \"POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-12T12:03:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc3OCMzOTEzMjgwIzIxOTQ1Njg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment","datePublished":"2021-01-12T12:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/"},"wordCount":407,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc3OCMzOTEzMjgwIzIxOTQ1Njg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/","name":"POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc3OCMzOTEzMjgwIzIxOTQ1Njg=","datePublished":"2021-01-12T12:03:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc3OCMzOTEzMjgwIzIxOTQ1Njg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzc3OCMzOTEzMjgwIzIxOTQ1Njg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/point-biopharma-signs-exclusive-license-agreement-with-canprobe-for-the-commercialization-of-a-neuroendocrine-tumor-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=412771"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412771\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=412771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=412771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=412771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}